Skip to main content Skip to section navigation Skip to footer
ProMIS Neurosciences, Inc.
  • Home
  • About Us
    • Overview
    • Management Team
    • Board of Directors
    • Scientific Advisory Board
    • Business Advisory Board
  • Our Science
  • Product Pipeline
    • Overview
    • Alzheimer’s Disease
    • ALS
    • Parkinson’s Disease
    • Posters & Publications
  • News & Media
    • Press Releases
    • Corporate Presentations
    • Events
    • In The News
    • Videos
    • Commentary
    • Podcasts
  • Investors
    • Overview
    • News & Events
    • Company Info
    • Financial Results
    • Stock Data
    • SEDAR
    • SEC Filings
    • Governance
  • Careers
  • Contact

Press Releases

Investors

Investors

  • Overview
  • News & Events
    • Overview
    • Press Releases
    • IR Calendar
    • Email Alerts
  • Company Info
    • Overview
    • Management Team
    • Presentations
    • Contacts
    • FAQ
  • Financial Results
  • Stock Data
    • TSX: PMN
    • OTCQB: ARFXF
    • Analyst Coverage
  • SEDAR
  • SEC Filings
  • Governance
    • Overview
    • Board of Directors
    • Board Committees
    • Governance Documents
  • News & Events

  • Overview
  • Press Releases
  • IR Calendar
  • Email Alerts
Apr 03, 2018 7:30am EDT

ProMIS Neurosciences Announces Appointment of Ernest Bush as Head of Pharmacology/Toxicology and Russell Blacher as Head of Manufacturing

Mar 20, 2018 7:30am EDT

ProMIS Neurosciences Appoints Dr. Sharon Cohen to Scientific Advisory Board

Mar 15, 2018 7:30am EDT

ProMIS Neurosciences to Present at Upcoming Investor Conferences

Mar 14, 2018 7:30am EDT

ProMIS Neurosciences Announces Fiscal Year 2017 Annual Results

Mar 07, 2018 7:30am EST

ProMIS Neurosciences Announces Gross Proceeds of $1,484,498 Related to the Exercise of Common Stock Warrants

Mar 06, 2018 7:30am EST

ProMIS Neurosciences Lead Product Candidate for Alzheimer's Disease Shows Potential for Improved Therapeutic Potency versus Other Amyloid Beta-Directed Antibodies

Jan 25, 2018 11:20am EST

ProMIS Neurosciences to Present at Upcoming Investor Conferences

Jan 25, 2018 7:30am EST

ProMIS Neurosciences Issues White Paper Entitled: "Not All Amyloid Beta Therapeutics Are Created Equal"

Jan 23, 2018 7:30am EST

ProMIS Neurosciences Lead Product Candidate for Alzheimer's Disease Shows Potential for Improved Therapeutic Potency versus Other Amyloid Beta-Directed Antibodies

Jan 22, 2018 11:04am EST

ProMIS Neurosciences Issues Response to Recent Market Activity

  • arrow_back
  • 1…
  • 9
  • 10
  • 11
  • 12
  • 13
  • 14
  • 15
  • 16
  • 17
  • 18
  • arrow_forward
  • Email Alerts
  • Contacts
Facebook Linkedin Spotify Twitter
©2022 ProMIS Neurosciences, Inc. All Rights Reserved.
Disclaimer Sitemap Cookie Policy Privacy Policy